Trial Results Show 'Something We Have Not Seen for Years' in Osteosarcoma

(MedPage Today) -- The investigational antibody-drug conjugate (ADC) risvutatug rezetecan (Ris-Rez) significantly improved progression-free survival (PFS) in patients with relapsed or refractory osteosarcoma, the phase III ARTEMIS-011 trial from...